Oncolytics Biotech Inc(ONCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ONCY Oncolytics Biotech Inc

Pre-Mkt 06-05 06:39:54 EDT

0.8670

-0.0130

-1.48%

盘前0.8690

+0.0020+0.23%

04:00 EDT

High0.9020	Low0.8507	Vol1.02M
Open0.8900	D1 Closing0.8800	Amplitude5.83%
Mkt Cap103.17M	Tradable Cap98.84M	Total Shares119.00M
T/O890.52K	T/O Rate0.89%	Tradable Shares114.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ONCY","market":"US","secType":"STK","nameCN":"Oncolytics Biotech Inc","latestPrice":0.867,"timestamp":1780603200000,"preClose":0.88,"halted":0,"volume":1019874,"hourTrading":{"tag":"盘前","latestPrice":0.869,"preClose":0.867,"latestTime":"04:00 EDT","volume":101,"amount":87.7670002,"timestamp":1780646409595,"change":0.002,"changeRate":0.002307,"amplitude":0.002307},"delay":0,"changeRate":-0.014772727272727286,"floatShares":113999999,"shares":119000000,"eps":-0.323929,"marketStatus":"Pre-Mkt","change":-0.013,"latestTime":"06-05 06:39:54 EDT","open":0.89,"high":0.902,"low":0.8507,"amount":890516.0374872,"amplitude":0.058295,"askPrice":0.95,"askSize":210,"bidPrice":0.8507,"bidSize":3,"shortable":3,"etf":0,"ttmEps":-0.323929,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1780666200000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1002254400000,"exchange":"NASDAQ","adjPreClose":0.867,"preHourTrading":{"tag":"盘前","latestPrice":0.869,"preClose":0.867,"latestTime":"04:00 EDT","volume":101,"amount":87.7670002,"timestamp":1780646409595,"change":0.002,"changeRate":0.002307,"amplitude":0.002307},"postHourTrading":{"tag":"盘后","latestPrice":0.8624,"preClose":0.867,"latestTime":"19:57 EDT","volume":6160,"amount":5377.1248,"timestamp":1780617420779,"change":-0.0046,"changeRate":-0.005306,"amplitude":0.046136},"volumeRatio":0.3257085131179023},"requestUrl":"/m/hq/s/ONCY","defaultTab":"news","newsList":[{"id":"2640817181","title":"Oncolytics Biotech COO John Bearden McAdory files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2640817181","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640817181?lang=en_us&edition=fundamental","pubTime":"2026-06-04 04:32","pubTimestamp":1780518754,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech COO McAdory John Bearden reported holding stock options for 500,000 common shares exercisable at $0.97, expiring Jan. 12, 2031.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 03, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nNDL9SyNHR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640769181","title":"Oncolytics Biotech director Stephen C. Glover files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2640769181","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640769181?lang=en_us&edition=fundamental","pubTime":"2026-06-04 04:31","pubTimestamp":1780518718,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech director Stephen C. Glover filed an initial Form 3 statement of beneficial ownership dated June 1.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 03, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nNDL5ph5H2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640490889","title":"Oncolytics promotes John McAdory to COO","url":"https://stock-news.laohu8.com/highlight/detail?id=2640490889","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640490889?lang=en_us&edition=fundamental","pubTime":"2026-06-02 22:21","pubTimestamp":1780410094,"startTime":"0","endTime":"0","summary":"Oncolytics (ONCY) announced the appointment of Steve Glover to its board of directors and the promotion of John McAdory to COO. Additionally, McAdo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oncolytics-promotes-john-mcadory-to-coo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oncolytics-promotes-john-mcadory-to-coo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1992135399.USD","LU2211815571.USD","BK4588","LU2272731600.USD","BK4198","BK4585","GB00BDT5M118.USD","COO","LU2272731782.SGD","ONCY","BK4139","LU1992135472.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640394378","title":"Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John Mcadory to Chief Operating Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2640394378","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640394378?lang=en_us&edition=fundamental","pubTime":"2026-06-02 21:00","pubTimestamp":1780405208,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nTUA8XMFG0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640957154","title":"Oncolytics announces initial data from pelareorep combination study","url":"https://stock-news.laohu8.com/highlight/detail?id=2640957154","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640957154?lang=en_us&edition=fundamental","pubTime":"2026-06-01 21:47","pubTimestamp":1780321660,"startTime":"0","endTime":"0","summary":"Oncolytics (ONCY) announced initial data from a preclinical study evaluating pelareorep in combination with RAS inhibitor modalities in a solid tum...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oncolytics-announces-initial-data-from-pelareorep-combination-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oncolytics-announces-initial-data-from-pelareorep-combination-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640952414","title":"Oncolytics Says Preclinical Results Back Further Evaluation of Pelareorep Plus RAS-Targeted Approaches","url":"https://stock-news.laohu8.com/highlight/detail?id=2640952414","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640952414?lang=en_us&edition=fundamental","pubTime":"2026-06-01 21:36","pubTimestamp":1780320989,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech  said Monday that initial results from a preclinical study assessing pelareorep plus RAS inhibitor modalities in a solid tumor model showed evidence of the combination's greater anti-tumor activity than with the individual approaches alone.The company said that, based on the results, it is planning further studies in models of pancreatic ductal adenocarcinoma and colorectal cancer to further assess the combinations' anti-tumor and immune effects.Full results from the initial preclinical studies are slated to be presented in the fall or winter of this year, Oncolytics said.The company's shares were up more than 8% in Monday premarket trading.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640954464","title":"Oncolytics Biotech reports positive preclinical data for pelareorep with RAS-targeted therapies in solid tumor model","url":"https://stock-news.laohu8.com/highlight/detail?id=2640954464","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640954464?lang=en_us&edition=fundamental","pubTime":"2026-06-01 21:02","pubTimestamp":1780318967,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech reported initial preclinical findings showing pelareorep combined with RAS-targeted approaches outperformed either approach alone in a solid tumor model.The results have not been fully presented yet; full data are expected in fall or winter 2026.The company plans additional studies in pancreatic ductal adenocarcinoma and colorectal cancer to assess immune activation, response durability, and time-to-resistance.The work targets RAS-mutated tumors, positioning pelareorep as a potential immune-priming backbone for next-generation targeted therapy combinations.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL15NF3Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","SG9999014021.USD","LU0314104364.USD","IE00BKPKM429.USD","SG9999014005.SGD","SG9999014013.SGD","LU2210149790.SGD","BK4139","IE00BGHQF748.EUR","NDAQ","BK4588","IE00BN0W2V16.EUR","BK4112","IE00B64PRP62.GBP","ONCY","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","BK4585","LU2210150020.SGD","SG9999014039.USD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637031704","title":"Oncolytics Biotech to present data at ASCO 2026 on pelareorep","url":"https://stock-news.laohu8.com/highlight/detail?id=2637031704","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637031704?lang=en_us&edition=fundamental","pubTime":"2026-05-22 21:45","pubTimestamp":1779457550,"startTime":"0","endTime":"0","summary":"Oncolytics (ONCY) Biotech announced translational data from the GOBLET and AWARE-1 trials will be presented at the 2026 American Society of Clinica...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oncolytics-biotech-to-present-data-at-asco-2026-on-pelareorep-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oncolytics-biotech-to-present-data-at-asco-2026-on-pelareorep-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4588","XBI","BK4585","ONCY","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637314778","title":"Oncolytics Biotech presents ASCO 2026 data from pelareorep trials in GI tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2637314778","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637314778?lang=en_us&edition=fundamental","pubTime":"2026-05-22 21:00","pubTimestamp":1779454859,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech flagged new translational results for its investigational immunotherapy pelareorep, with data from the GOBLET and AWARE-1 studies scheduled for presentation at the ASCO Annual Meeting in Chicago on May 30, 2026.The analyses point to an immune-activation sequence in which treatment amplifies existing tumor-reactive immune cells, linking that response to tumor shrinkage signals in advanced pancreatic cancer.Findings also suggest activity in hard-to-treat KRAS-driven disease, including expansion of mutant KRAS-specific T-cell clones, supporting the drug’s positioning across gastrointestinal tumors.In early-stage breast cancer, tumor biopsies indicated increased antiviral and immune signaling consistent with inflammatory immune remodeling, including features associated with tertiary lymphoid structure formation.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nNDL8N8tjC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","SG9999014021.USD","IE00B64PRP62.GBP","LU2210150020.SGD","SG9999014005.SGD","SG9999014039.USD","IE00B3QW5Z07.USD","NDAQ","IE00BGHQF748.EUR","SG9999014013.SGD","IE00BN0W2T93.GBP","BK4588","BK4139","ONCY","IE00BKPKM429.USD","IE00BN0W2W23.USD","LU2095319765.USD","LU0314104364.USD","BK4585","BK4112","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635472504","title":"Oncolytics net loss more than doubled to $9.24 million in Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2635472504","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635472504?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:32","pubTimestamp":1778790720,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech posted a net loss of USD 9.24 million for the quarter ended March 31, 2026, widening from USD 4.71 million a year earlier.Research and development expense climbed 62.57% to USD 4.55 million, driven by higher personnel costs and startup spending for a randomized Phase 2 second-line metastatic colorectal cancer study.General and administrative expense more than doubled to USD 4.73 million, on higher public company-related costs tied to investor relations activity and professional fees related to the Domestication.Cash and cash equivalents edged up to USD 5.49 million; operating cash outflow widened to USD 7.29 million.Fast Track Designation was granted in 2026 for pelareorep with bevacizumab and FOLFIRI in KRAS-mutant, microsatellite-stable second-line mCRC; an open market sale agreement with Jefferies allows up to USD 75 million of common stock sales.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDL9Lr6HL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633696941","title":"Lake Street Sticks to Its Buy Rating for Oncolytics Biotech (ONCY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633696941","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633696941?lang=en_us&edition=fundamental","pubTime":"2026-05-05 22:55","pubTimestamp":1777992958,"startTime":"0","endTime":"0","summary":"Lake Street analyst Chad Messer maintained a Buy rating on Oncolytics Biotech today and set a price target of $5.00. According to TipRanks, Messer ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lake-street-sticks-to-its-buy-rating-for-oncolytics-biotech-oncy-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lake-street-sticks-to-its-buy-rating-for-oncolytics-biotech-oncy-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONCY","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632955426","title":"BRIEF-Oncolytics Biotech® Reports Durable Responses In Second-Line Ras-Mutant Mss Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2632955426","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632955426?lang=en_us&edition=fundamental","pubTime":"2026-05-04 21:09","pubTimestamp":1777900170,"startTime":"0","endTime":"0","summary":"BRIEF-Oncolytics Biotech Reports Durable Responses In Second-Line Ras-Mutant Mss Colorectal CancerMay 4 (Reuters) - Oncolytics Biotech Inc ONCY.O:ONCOLYTICS BIOTECH REPORTS DURABLE RESPONSES IN SECOND","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nTUA6HLQPV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632955669","title":"Oncolytics says pelareorep combo shows 19.5-month response duration in Phase 2 mCRC study","url":"https://stock-news.laohu8.com/highlight/detail?id=2632955669","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632955669?lang=en_us&edition=fundamental","pubTime":"2026-05-04 21:00","pubTimestamp":1777899635,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech disclosed new durability results from REO 022 in second-line RAS-mutant, microsatellite-stable metastatic colorectal cancer, with results already presented as new data in its update.Pelareorep-based combination therapy showed sustained tumor response versus typical outcomes in this treatment setting.Response activity also compared favorably with standard care benchmarks, supporting a stronger clinical benefit profile.Company is enrolling a randomized Phase 2 study of pelareorep with FOLFIRI and bevacizumab in the same population.FDA discussions are underway on a potential accelerated approval path, centered on response durability and time-to-event measures from the ongoing trial.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDL3pJC2G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00B64PRP62.GBP","SG9999014005.SGD","IE00B3QW5Z07.USD","BK4588","BK4139","IE00BN0W2W23.USD","SG9999014013.SGD","NDAQ","LU0314104364.USD","ONCY","IE00BKPKM429.USD","LU2210150020.SGD","IE00BN0W2T93.GBP","LU2210149790.SGD","LU2095319765.USD","IE00BGHQF748.EUR","BK4585","IE00BN0W2V16.EUR","BK4112","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632955127","title":"Oncolytics Biotech Inc - 2L Kras-Mutant Mss Mcrc Demonstrates 3-4X Improvement in Duration of Response VS. Historical 4-6 Month Benchmark","url":"https://stock-news.laohu8.com/highlight/detail?id=2632955127","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632955127?lang=en_us&edition=fundamental","pubTime":"2026-05-04 21:00","pubTimestamp":1777899600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nTUA6HLQPV:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632955119","title":"Oncolytics Biotech Inc - Pelaeoreorep Combination Shows 19.5-Month Median Duration of Response in 2L Kras-Mutant Mss Mcrc","url":"https://stock-news.laohu8.com/highlight/detail?id=2632955119","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632955119?lang=en_us&edition=fundamental","pubTime":"2026-05-04 21:00","pubTimestamp":1777899600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nTUA6HLQPV:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632955114","title":"Oncolytics Biotech Inc - Engaged With FDA on Accelerated Approval Pathway for 2L Ras-Mutant Mss Mcrc","url":"https://stock-news.laohu8.com/highlight/detail?id=2632955114","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632955114?lang=en_us&edition=fundamental","pubTime":"2026-05-04 21:00","pubTimestamp":1777899600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nTUA6HLQPV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630898583","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Oncolytics Biotech (ONCY) and Agilon Health (AGL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2630898583","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630898583?lang=en_us&edition=fundamental","pubTime":"2026-04-28 22:00","pubTimestamp":1777384835,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Oncolytics Biotech (ONCY) and Agilon Health (AGL)....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-oncolytics-biotech-oncy-and-agilon-health-agl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-oncolytics-biotech-oncy-and-agilon-health-agl-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","XLV","BK4581","LU0128526141.USD","LU0029874061.USD","BK4196","LABU","BK4139","BK4588","BK4585","XBI","ONCY","AGL","BK4137","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630392596","title":"Oncolytics says in alignment with FDA following pelareorep Type C meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2630392596","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630392596?lang=en_us&edition=fundamental","pubTime":"2026-04-27 21:19","pubTimestamp":1777295945,"startTime":"0","endTime":"0","summary":"Oncolytics (ONCY) announced that a Type C meeting with the FDA has resulted in alignment on the design of a pivotal clinical study to support appro...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oncolytics-says-in-alignment-with-fda-following-pelareorep-type-c-meeting-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oncolytics-says-in-alignment-with-fda-following-pelareorep-type-c-meeting-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4139","LABU","BK4588","ONCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630399322","title":"Oncolytics Biotech Inc - Announces Alignment With FDA on Pivotal Anal Cancer Study - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2630399322","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630399322?lang=en_us&edition=fundamental","pubTime":"2026-04-27 20:19","pubTimestamp":1777292384,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nFWN41A07E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ONCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630396005","title":"Oncolytics aligns with FDA on pivotal pelareorep anal cancer trial design","url":"https://stock-news.laohu8.com/highlight/detail?id=2630396005","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630396005?lang=en_us&edition=fundamental","pubTime":"2026-04-27 20:14","pubTimestamp":1777292084,"startTime":"0","endTime":"0","summary":"Oncolytics Biotech aligned with FDA on design of a pivotal trial for pelareorep in unresectable metastatic squamous cell carcinoma of anal canal.Study will use a randomized controlled design intended to support accelerated approval and full approval from a single trial.Plan targets patients whose disease progressed after standard first-line therapy, a setting with no FDA-approved treatment options.Prior study results in second-line or later disease were already presented, showing signs of more durable responses and improved survival versus current standard of care.Company expects to incorporate FDA feedback into final protocol for the pivotal study.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nNDL9Jv7B8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","ONCY","LU2210150020.SGD","IE00B64PRP62.GBP","SG9999014013.SGD","IE00BGHQF748.EUR","BK4588","SG9999014005.SGD","IE00BKPKM429.USD","LU0314104364.USD","IE00BN0W2T93.GBP","SG9999014039.USD","BK4112","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","BK4585","LU2210149790.SGD","BK4139","NDAQ","SG9999014021.USD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.oncolyticsbiotech.com","stockEarnings":[{"period":"1week","weight":-0.0727},{"period":"1month","weight":-0.0525},{"period":"3month","weight":-0.1821},{"period":"6month","weight":-0.1261},{"period":"1year","weight":1.5508},{"period":"ytd","weight":-0.008}],"compareEarnings":[{"period":"1week","weight":0.0033},{"period":"1month","weight":0.046},{"period":"3month","weight":0.126},{"period":"6month","weight":0.1041},{"period":"1year","weight":0.2704},{"period":"ytd","weight":0.1102}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.001975},{"month":2,"riseRate":0.25,"avgChangeRate":-0.025046},{"month":3,"riseRate":0.125,"avgChangeRate":-0.123611},{"month":4,"riseRate":0.75,"avgChangeRate":0.024604},{"month":5,"riseRate":0.375,"avgChangeRate":0.014597},{"month":6,"riseRate":0.25,"avgChangeRate":0.145958},{"month":7,"riseRate":0.5,"avgChangeRate":0.009647},{"month":8,"riseRate":0.25,"avgChangeRate":-0.092405},{"month":9,"riseRate":0.125,"avgChangeRate":-0.025103},{"month":10,"riseRate":0.5,"avgChangeRate":0.144514},{"month":11,"riseRate":0.25,"avgChangeRate":0.020161},{"month":12,"riseRate":0.125,"avgChangeRate":0.270533}],"exchange":"NASDAQ","name":"Oncolytics Biotech Inc","nameEN":"Oncolytics Biotech Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Oncolytics Biotech Inc(ONCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Oncolytics Biotech Inc(ONCY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Oncolytics Biotech Inc,ONCY,Oncolytics Biotech Inc股票,Oncolytics Biotech Inc股票老虎,Oncolytics Biotech Inc股票老虎国际,Oncolytics Biotech Inc行情,Oncolytics Biotech Inc股票行情,Oncolytics Biotech Inc股价,Oncolytics Biotech Inc股市,Oncolytics Biotech Inc股票价格,Oncolytics Biotech Inc股票交易,Oncolytics Biotech Inc股票购买,Oncolytics Biotech Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Oncolytics Biotech Inc(ONCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Oncolytics Biotech Inc(ONCY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}